What is HC Wainwright’s Estimate for PTGX Q1 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Investment analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for Protagonist Therapeutics in a report released on Monday, February 24th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.57) per share for the quarter, up from their prior estimate of ($0.61). HC Wainwright has a “Buy” rating and a $54.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at $1.00 EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($1.52) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at $2.83 EPS and FY2029 earnings at $6.91 EPS.

A number of other brokerages have also recently weighed in on PTGX. Wedbush reiterated an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 21st. JMP Securities restated a “market outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research report on Friday, February 7th. JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $51.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. BMO Capital Markets started coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $62.00 price target on the stock. Finally, StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.44.

Protagonist Therapeutics Stock Up 3.0 %

NASDAQ:PTGX opened at $36.15 on Wednesday. The business’s 50 day moving average is $38.09 and its two-hundred day moving average is $41.85. Protagonist Therapeutics has a 52 week low of $24.22 and a 52 week high of $48.89. The company has a market cap of $2.15 billion, a PE ratio of 13.59 and a beta of 2.22.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of Montreal Can lifted its position in shares of Protagonist Therapeutics by 4.5% in the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after buying an additional 270 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in Protagonist Therapeutics by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after acquiring an additional 278 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after purchasing an additional 295 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock valued at $1,112,000 after purchasing an additional 300 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Protagonist Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock valued at $95,000 after purchasing an additional 379 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now owns 540,260 shares in the company, valued at $20,627,126.80. The trade was a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 5.40% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.